Skip to main content

Outcomes

Birthday Gatherings Increase COVID-19 Risk

Jun 24, 2021

How risky are family gatherings, birthday parties and informal social gatherings? A cross-sectional analysis suggests that birthdays may be associated with increased rates of COVID-19 infection within households where there is a high COVID-19 prevalence in the population. 

Read Article

Knee Replacement in Obese OA is Cost Effective

Jun 24, 2021

Debates over ideal candidates for total knee replacement (TKR) in osteoarthritis patients often excludes those who are obese, but a recent article in the Annals of Internal Medicine suggests that TKR is both effective and cost-effective in obese patients (BMI >40 kg/m2)

Read Article

Better Outcomes with Modern T2T in Pregnancy

Jun 23, 2021

With the expansion of knowledge regarding the safety of newer agents in pregnancy comes the PreCARA study showing that when pregnancy is planned and patients with rheumatoid arthritis (RA) are treated with a modified treat-to-target (T2T) approach, superior outcomes can be anticipated.

Read Article

Progression from Psoriasis to Psoriatic Arthritis

Jun 22, 2021

The question of whether psoriasis is a state or pre-clinical psoriatic arthritis has been addressed by several studies; with one suggesting that biologic use in psoriasis may aver the future development of psoratic arthritis (PsA).



A retrospecitve analysis of non-randomized moderate-

Read Article

FINCH 1 Trial Filgotinib in Rheumatoid Arthritis

Jun 22, 2021

The Annals of Rheumatic Disease has published the results of a head-to-head trial showing that the Janus kinase-1 (JAK1) preferential inhibitor filgotinib was superior to a tumour necrosis factor-α inhibitor (adalimumab) in active rheumatoid arthritis (RA) on methotrexate (MTX).

Read Article

Treatment of MIS-C COVID in Kids

Jun 21, 2021

The NEJM has published results of a real-world efficacty trial showing that COVID infected children with the multisystem inflammatory syndrome in children (MIS-C) respond better to initial IVIG plus glucocorticoids (than IVIG alone) which was associated with less subsequent cardiovascular

Read Article

Which patients with psoriasis are at risk to develop PsA?

The potential transition from psoriasis (PsO) to psoriatic arthritis (PsA) has not been a strong focus for several years but is gaining momentum.



Many patients do have psoriasis before onset of symptoms. This question can either be explored retrospectively using existing data or

Read Article

EULAR 2021 – Day 4 Report

Jun 17, 2021

It's been nearly two weeks since EULAR 21 ended. There were several presentations on the last day; notably, the late breaking abstracts and others. Here are a few of my favorites from Day 4, the final day of the meeting.

Read Article

RheumNow Podcast - Best of EULAR 2021

Jun 11, 2021

Dr. Jack Cush reviews and highlights his favorite abstracts and presentations from last week's virtual EULAR 2021 meeting.

Read Article

How Do You Measure Success When It Comes to SLE?

Jun 10, 2021

EULAR 2021 opened with a grand debate to answer this essential question:  should clinicians treat to remission or to Lupus Low Disease Activity State (LLDAS)?  

Read Article

Novel TYK2 Inhibitor Efficacious for Treatment of Psoriatic Arthritis

Dr. Philip Mease et al presented results of a phase II trial (OP0227) at EULAR 2021 that shows the efficacy and safety of an oral tyrosine kinase inhibitor (TYKi), deucravacitinib, for treatment of active psoriatic arthritis (PsA).

Read Article
EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021
#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2021

EULAR 2021 - Day 2 Podcasts

Jun 04, 2021

Check out this compilation of our EULAR 2021 Day 2 broadcasts below.



You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud.com



Listen by Clicking below:



1. EULAR2021 - Day2a



Read Article

RheumNow Podcast - EULAR 2021 & EULAR-IQ (6.4.21)

Jun 04, 2021

Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021.


Read Article

EULAR 2021 – Day 2 Report

Jun 04, 2021

During Day 2 there were great sessions devoted to RA, spondylarthritis, fatigue and more.  Here are some of my highlights from Day 2.

Read Article

EULAR 2021 – Day 1 Report

Jun 03, 2021

After the opening ceremonies and keynote speaker there were several enticing sessions and a plenary session full of great research and presentations.  Here are a few of the highlights that I saw.

Read Article
Prof. Alten outlined the value of patient-reported outcomes for clinical practice! How do you collect patient-reported outcomes - PRO - in your rheumatology clinic? #EULAR2021 @RheumNow

Paul Studenic @Stiddyo( View Tweet )

Jun 02, 2021

Foot Pain Commonly Overlooked in RA

MedPage Today
Jun 01, 2021

Foot pain is a common but underappreciated symptom of rheumatoid arthritis (RA) and can be associated with worse disease, European researchers found.



In a cohort of 320 patients with RA, 69% reported foot or ankle pain, according to Morten Bilde Simonsen, PhD, of Aalborg University in

Read Article

Best Interventions for Gout Flares

May 31, 2021

A recent metanalysis assessed the comparative efficacy of current first-line pharmacologic antiinflammatory interventions for gout flares and surmised that canakinumab and intravenous or intramuscular corticosteroids are superior to  nonsteroidal antiinflammatory drugs [NSAIDs].



From

Read Article

COLCORONA: Protective Effect of Colchicine in COVID-19

May 31, 2021

Lancet Respiratory Medicine has reported the results of the COLCORONA trial, showing that in patients with PCR-confirmed COVID-19 infection, colchicine led to a significantly lower rate of death or hospital admission from COVID.



Colchicine is an oral anti-inflammatory agent with

Read Article

RheumNow Podcast – Heart, Lung & Liver (5.28.2021)

May 27, 2021

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article

Methotrexate Impairs COVID Vax Response

MedPage Today
May 27, 2021

One-third of patients with immune-mediated inflammatory diseases being treated with methotrexate showed attenuated responses to the COVID-19 vaccine, researchers reported.



In two independent cohorts, robust antibody responses were observed in 98.1% of healthy controls and in 91.9% of

Read Article

Efficacy of 6 Weeks Antibiotics with Prosthetic Joint Infections

May 27, 2021

The NEJM has published the results of a French multicenter study showing that prosthetic joint infections can be successfully managed with 6 weeks of antibiotic therapy; this was noninferior and had better outcomes compared to 12 weeks of antibiotic therapy.



Prosthetic joint

Read Article

Triple DMARD Therapy Bested by Biologics in Swedish Registry

May 26, 2021

The Swedish Register compared outcomes of 1502 rheumatoid arthritis (RA) patients initiating either biologics plus methotrexate (MTX) or triple therapy (MTX plus sulfasalazine plus hydroxychloroquine/chloroquine) and showed similar rates of sustained remission.



Sustained remission was

Read Article
×